

This application is a divisional of application Serial No. 08/934,659, filed September 22, 1997, allowed; which is a continuation of application Serial No. 08/483,165, filed June 7, 1995, now U.S. Patent No. 5,876,922; which is a continuation of 08/274,159, filed July 14, 1994, now U.S. Patent No. 5,712,092; which is a continuation of Serial No. 07/914,002, filed July 16, 1992, now abandoned; which is a continuation of Serial No. 07/758,421, filed September 3, 1991, now abandoned; which is a continuation of Serial No. 07/624,463, filed December 10, 1990, now abandoned; which is a continuation of Serial No. 07/453,218, filed December 21, 1989, now abandoned; which is a continuation of Serial No. 07/276,388, filed November 25, 1988, now abandoned; which is a continuation of Serial No. 07/159,442, filed February 18, 1988, now abandoned; which is a continuation of Serial No. 06/760,993, filed July 31, 1985, now abandoned; all of which are hereby incorporated by reference.

IN THE CLAIMS:

Please cancel claims 1-9 without prejudice or disclaimer.

Please add the following new claims.

--10. (NEW) A serum for inducing remission of a human papillomavirus (HPV) infection, said serum produced by immunizing a mammal with an immunogenic composition, wherein said immunogenic composition comprises a polypeptide encoded by a DNA of a human papillomavirus, wherein said DNA is about 7,000 to about 8,000 base pairs, and wherein said human papillomavirus is selected from the group consisting of HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b,

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000